A comprehensive insight into effects of resveratrol on molecular mechanism in rheumatoid arthritis: A literature systematic review

Aim Rheumatoid arthritis (RA) is an inflammatory autoimmune disease, which is characterized by massive pain and destruction of synovial joints, leads to bone erosion, damage to cartilage, and disability. Several studies suggested that resveratrol supplementation may be effective in the prevention and management of RA. Therefore, a systematic review was conducted to summarize published studies that assess the effect of resveratrol supplementation on the complications of RA. Methods A comprehensive search to identify in vitro, animal, and human studies investigating the impact of resveratrol on the complications of RA was performed up to February 2022. Two independent reviewers evaluated studies based on inclusion/exclusion criteria and performed data extraction. Results All studies examining the effects of resveratrol supplementation on the complications of RA were included. From a total of 571 retrieved articles, 32 studies were eligible for the current systematic review. The evidence reviewed here indicates that resveratrol supplementation may exert beneficial effects on the complications of RA by attenuating inflammation and oxidative stress, modulating the immune response, and down-regulating the messenger RNA expression of genes related to inflammatory pathways. Conclusion Due to the promising therapeutic effects of resveratrol on RA complications and limited number of human studies in this subject, further clinical trials are suggested.

Automated summary

This systematic review summarizes the effects of resveratrol supplementation on complications of rheumatoid arthritis (RA). The review suggests that resveratrol supplementation may have beneficial effects on RA complications by reducing inflammation and oxidative stress, modulating the immune response, and down-regulating the expression of genes related to inflammatory pathways. However, due to the limited number of human studies, further clinical trials are warranted.